Monitoring efficacy, safety and tolerability of ezetimibe added to simvastatin in hypercholesterolemic patients using hospital information system

運用醫院資訊系統監測ezetimibe加入simvastatin治療高血壓病人的療效、安全性及耐受性

Purpose: To monitor the effect, safety and tolerability of ezetimibe added to simvastatin in hypercholesterolemic patients using the hospital information system. Methods: A randomized control study was designed to evaluate the treatment goal attainment, safety and tolerability of ezetimibe added to simvastatin for the hypercholesterolemic patients in 4, 8 and 16 weeks. Results and Discussion: Treatment goals of lowering LDL-C, T-cholesterol , TG and elevating HDL-C were 71.2mg/dl (37.9%), 76.0mg/dl (31.1%), 34.0mg/dl (28.6%) and 3.0mg/dl (4.8%) in a simvastatin latter added ezetimibe group and 83.2mg/dl (49.6%), 86.0mg/dl (36.3%), 53.0mg/dl (34.9%) and 1.0mg/dl (3.0%) in an ezetimibe latter added simvastatin group, respectively. The ezetimibe simvastatin combination was no clinically significant elevations in hepatic transaminase or creatinine kinase and measures of hematology did not show any clinically significant differences. Conclusions: Ezetimibe was effective and well tolerated in this study, and ezetimibe was added to simvastatin that also found more significant lowering LDL-C, T-cholesterol and triglyceride and elevating HDL-C.

目的：運用醫院資訊系統監測高膽固醇血症患者中加入辛伐他汀的依澤替米貝的療效，安全性和耐受性。方法：設計了一項隨機對照研究，以評估高膽固醇血症患者在4週、8周和16週內加入辛伐他汀的依澤替米貝的治療目標達成率，安全性和耐受性。結果與討論：降低LDL-C，T-膽固醇，TG和升高HDL-C的治療目標分別為71.2mg / dl（37.9%），76.0mg / dl（31.1%），34.0mg / dl（28.6%）和在辛伐他汀中加入3.0mg / dl（4.8%），之後加入易澤西組和83.2mg / dl（49.6%），86.0mg / dl（36.3%），53.0mg / dl（34.9%）和1.0mg / dl（3.0%）在依澤替米貝中分別加入辛伐他汀組。依澤替米貝辛伐他汀聯合用藥在肝轉氨酶或肌酐激酶方面無臨床意義的明顯升高，血液學指標也無任何臨床意義的差異。結論：依澤替米貝在這項研究中有效且耐受性好，依澤替米貝加到辛伐他汀中，還發現降低LDL-C，T-膽固醇和甘油三酸酯和升高HDL-C更為顯著。